Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Vet Med Sci ; 86(7): 727-736, 2024 Jul 02.
Artigo em Inglês | MEDLINE | ID: mdl-38825481

RESUMO

L-Asparaginase (L-Asp) is often used to induce remission in feline large-cell gastrointestinal lymphoma (LCGIL). However, no study has evaluated the efficacy and adverse events following the initial use of this drug as a first-line treatment in feline LCGIL. We retrospectively reviewed medical records of cats with LCGIL treated with L-Asp to induce remission. This study included 43 cats. The response rate (RR) after the first administration of L-Asp was 37.2% (Complete remission: 7.0%, partial remission: 30.2%). RR was significantly higher in cases with primary gastric lesions (64.3%) than in those with primary intestinal lesions (24.1%) (P=0.018), and it was also higher in cases without anemia (57.1%) than those with anemia (15.0%) (P=0.009). The most common adverse event was hyperammonemia, which occurred in 10 of 12 cases where we could compare plasma ammonia concentrations before and after the first dose of L-Asp. Plasma phosphate concentrations were also significantly increased (P<0.001) within 24 hr after the first dose. Decreased appetite, vomiting, and diarrhea were also observed in five, three, and seven cases, respectively, and Grade 3 or higher gastrointestinal signs were observed as adverse events in three cases. The median overall survival of all cats was 150 days (range, 5-1,065 days), and the median progression-free survival was 104 days (range, 2-978 days). In conclusion, L-Asp was effective to induce remission, and severe adverse events were uncommon in feline LCGIL.


Assuntos
Antineoplásicos , Asparaginase , Doenças do Gato , Neoplasias Gastrointestinais , Gatos , Animais , Asparaginase/efeitos adversos , Asparaginase/administração & dosagem , Asparaginase/uso terapêutico , Doenças do Gato/tratamento farmacológico , Doenças do Gato/induzido quimicamente , Masculino , Feminino , Estudos Retrospectivos , Neoplasias Gastrointestinais/tratamento farmacológico , Neoplasias Gastrointestinais/veterinária , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Antineoplásicos/administração & dosagem , Resultado do Tratamento , Linfoma/tratamento farmacológico , Linfoma/veterinária , Indução de Remissão
2.
J Vet Med Sci ; 86(1): 18-27, 2024 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-37952972

RESUMO

Although chemotherapy using CHOP-based protocol induces remission in most cases of canine multicentric high-grade B-cell lymphoma (mhBCL), some cases develop early relapse during the first induction protocol. In this study, we examined the gene expression profiles of canine mhBCL before chemotherapy and investigated their associations with early relapse during the first whole CHOP-based protocol. Twenty-five cases of mhBCL treated with CHOP-based protocol as first induction chemotherapy were included in this study. Sixteen cases completed the first whole CHOP-based protocol without relapse (S-group), and nine developed relapse during the chemotherapy (R-group). RNA-seq was performed on samples from neoplastic lymph nodes. Differentially expressed genes (DEGs) were extracted by the comparison of gene expression profiles between S- and R-groups, and the differences in the expression levels of these genes were validated by RT-qPCR. Extracted 179 DEGs included the genes related to chemokine CC motif ligand, T-cell receptor signaling pathway, and PD-L1 expression and PD-1 checkpoint pathway. We focused on chemokine CC motif ligand, and CCL4 was confirmed to be significantly downregulated in the R-group (P=0.039). We also focused on the genes related to T-cell signaling pathway, and CD3E (P=0.039), ITK (P=0.023), and LAT (P=0.023) genes were confirmed to be significantly upregulated in the R-group. The current results suggest that both changes in tumor cells and the interactions between tumor cells and immune cells are associated with the efficacy of the chemotherapy for first remission induction.


Assuntos
Doenças do Cão , Linfoma de Células B , Animais , Cães , Transcriptoma , Ligantes , Recidiva Local de Neoplasia/veterinária , Linfoma de Células B/tratamento farmacológico , Linfoma de Células B/genética , Linfoma de Células B/veterinária , Vincristina/uso terapêutico , Doxorrubicina/uso terapêutico , Indução de Remissão , Doença Crônica , Quimiocinas/uso terapêutico , Doenças do Cão/tratamento farmacológico , Doenças do Cão/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...